ReviewCurrent nutrition reports2025
Taurine in Type 2 Diabetes: Plasma Concentrations, Metabolic Pathways, and Potential as a Therapeutic Adjuvant.
Review in Current nutrition reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purpose of reviewThis narrative review aims to synthesize evidence regarding plasma taurine concentrations in individuals with type 2 diabetes mellitus (T2DM), explore the underlying mechanisms involved and evaluate the therapeutic potential of taurine as an adjuvant treatment. Finally, it highlights key knowledge gaps and perspectives for future clinical research. Taurine, a sulfur-containing amino acid, exhibits notable antioxidant and anti-inflammatory properties. It plays essential roles in glucose homeostasis, osmoregulation, mitochondrial protection, and the neutralization of reactive and toxic compounds. T2DM, the most common form of diabetes, is characterized by insulin resistance, pancreatic β-cell dysfunction, low-grade systemic inflammation, and oxidative stress-factors that aggravate glucose dysregulation and cellular damage. Although lifestyle interventions are the cornerstone of T2DM management, there is growing interest in complementary therapies that target these molecular dysfunctions. RECENT
findingsPlasma taurine concentrations have been found to be reduced in individuals with T2DM, likely due to impaired reabsorption, increased renal excretion, and elevated tissue demand caused by hyperglycemia and chronic inflammation. Experimental studies suggest that taurine supplementation can enhance insulin secretion, improve insulin signaling via the PI3K/Akt pathway, and modulate GLP-1 release. Preliminary human trials also indicate improvements in insulin sensitivity and fasting glucose levels. Taurine is essential for metabolic and cellular homeostasis, with reduced levels observed in individuals with type 2 diabetes. Emerging evidence suggests its supplementation may help counteract diabetes-related metabolic dysfunctions, supporting its potential as a complementary therapeutic strategy.
Indexed as
Identifiers
41217691What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.